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Abstract Ischemic heart disease (IHD) is the leading
cause of death worldwide. Novel cardioprotective strate-
gies are therefore required to improve clinical outcomes in
patients with IHD. Although a large number of novel car-
dioprotective strategies have been discovered in the
research laboratory, their translation to the clinical setting
has been largely disappointing. The reason for this failure
can be attributed to a number of factors including the
inadequacy of the animal ischemia–reperfusion injury
models used in the preclinical cardioprotection studies and
the inappropriate design and execution of the clinical car-
dioprotection studies. This important issue was the main
topic of discussion of the UCL-Hatter Cardiovascular
Institute 6th International Cardioprotection Workshop, the
outcome of which has been published in this article as the
‘‘Hatter Workshop Recommendations’’. These have been
proposed to provide guidance on the design and execution
of both preclinical and clinical cardioprotection studies in
order to facilitate the translation of future novel cardio-
protective strategies for patient beneﬁt.
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Introduction
Ischemic heart disease (IHD) is the leading cause of death
worldwide. As such, novel therapeutic strategies for pro-
tecting the heart against ischemia–reperfusion injury (IRI)
are urgently needed to: reduce myocardial injury, preserve
cardiac function, prevent the development of heart failure,
and improve clinical outcomes in patients with IHD
[42, 66]. However, a major obstacle to this process has
been the inability to successfully translate novel cardio-
protective strategies discovered in the research laboratory
setting directly into the clinical arena [38].
This important issue was the main topic of discussion
of the 6th Hatter Institute International Workshop on
Cardioprotection, which was held this year in Mauritius, an
Island in which diabetes and associated IHD are major
contributors to overall morbidity and mortality. It was
organized together with the Working Group of Cellular
Biology of the Heart of the European Society of Cardiol-
ogy. The main agenda of this International Workshop was
to discuss and formulate a set of recommendations for the
design and execution of future studies on cardioprotection
in both the research laboratory and the clinical setting, in
order to facilitate the translation of future novel cardio-
protective strategies for patient beneﬁt. One crucial aspect
of this endeavour was to recognise the limitations in the
design and execution of current experimental laboratory
and clinical cardioprotection studies, a feature which was
also highlighted by the NHLI Working Group in 2004 [7].
Inadequacy of the animal models of IRI
It is well accepted that the majority of animal models of IRI
currentlyusedto investigate novel cardioprotective strategies
are inadequate representations of the clinical setting [7, 33,
36, 56], given the size and age of the animals used as well as
their lack of co-morbidities and co-treatments. Ideally, one
would have to prove efﬁcacy of a certain cardioprotective
intervention in animal experiments by the reduction in
myocardial infarct (MI) size and/or improvement of prog-
nosis under all mimicked clinical circumstances; however,
this is unrealistic and it was agreed that the following rec-
ommendations should be proposed.
Animal selection
1. Species The response of the heart to IRI and cardio-
protective strategies will vary depending on the species
used. Often small animal MI models have been used to
investigate cardioprotection, since knockout and/or
silencing of target proteins is possible in these models.
However, more expensive, large animal (canine, por-
cine, primate) MI models are needed to conﬁrm results
of small animal experiments before clinical testing,
since the temporal and spatial development of MI as
well as certain signalling pathways in small animals
differ from that in larger mammals and humans [21,
53, 55]. Therefore, small animal MI models may be
used for preliminary ‘screening’ of a novel cardio-
protective strategy, as long as the latter is also dem-
onstrated to be efﬁcacious in at least one large animal
MI model.
2. Age Patients with IHD usually present between the
ages of 55 and 65 years, whereas many experimental
studies use young adult rats and mice (aged
3–4 months) which are equivalent to the human age
of 7–10 years [6]. Several studies have reported that
with age the myocardium can become resistant to
various cardioprotective strategies including ischemic
preconditioning [48] and postconditioning [5, 44].
Therefore, it is essential to demonstrate that any novel
cardioprotective strategy is effective in suitably aged
animal hearts. The easiest and most convenient species
for such experiments are mice and rats in which the
human age of 55–65 years corresponds to about
21–24 months of age [6].
3. Sex Both male and female patients suffer from IHD,
yet most preclinical cardioprotective studies are
restricted to using male animals only. Several studies
suggest that gender can impact on the myocardial
sensitivity to different cardioprotective strategies [15,
56]. Therefore, it is necessary to establish whether or
not a novel cardioprotective strategy is effective in
both male and female animals.
4. Co-morbidities Patients with IHD are likely to have a
number of co-morbid conditions at the time of
presentation, many of which can inﬂuence the sensi-
tivity of the myocardium to certain cardioprotective
strategies [15]. Preclinical studies suggest that in the
presence of diabetes [45, 50, 62] or the metabolic
syndrome [63], the threshold for cardioprotection may
be elevated or cardioprotection may be even absent
(reviewed in [15]). Therefore, it is essential to establish
whether or not a novel cardioprotective strategy is
effective in the presence in one or more of these co-
morbidities.
5. Medical therapy Many patients with pre-existing IHD
take several types of medical therapy which may
inﬂuence the effects of any novel cardioprotective
strategy. Certain sulphonylureas such as glibenclamide
may block the cardioprotection elicited by ischemic
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123conditioning [39]. On the other hand, nicorandil, ACE-
inhibitors, nitrates, statin therapy may inadvertently
precondition the myocardium. Furthermore, on admis-
sion with an MI, additional therapy such as oxygen,
morphine and nitrates may all precondition the myo-
cardium or at least lower the threshold for protection.
Similarly, patients undergoing elective coronary artery
bypass graft (CABG) surgery are likely to receive
inhalational anaesthetics such as isoﬂurane which has
been reported to precondition the heart [58]. It is
difﬁcult to reproduce all concomitant therapy in
preclinical animal models of cardioprotection but it
is crucial to be aware of the limitations of such models
without medication especially when co-morbidities are
present. In designing the preclinical experiment to take
all these factors into consideration, it may not be
feasible or necessary to allow for every different
combination and permutation. It may well be that
prioritizing the confounders and medical therapy is
more useful. In this respect, we would recommend that
it is more important to address age before gender and
the other co-morbidities. In terms of concomitant
medical therapy, we would recommend the investiga-
tion of at least one relevant medical therapy.
The animal model of IRI
1. The type of model Acute coronary occlusion in animal
models of MI is most often achieved by external
occlusion of a healthy coronary artery. In contrast, in
most patients presenting with an acute MI, the acute
coronary occlusion is due to the formation of a
thrombus at the site of a ruptured unstable athero-
sclerotic plaque. Furthermore, the process of reper-
fusion by percutaneous coronary intervention (PCI) in
the clinical setting is more likely to be associated
with a residual stenosis and with thrombotic emboli-
sation than in the animal model [24]. Thus, the nature
of the coronary artery occlusion and the methods used
to re-establish perfusion in addition to the pro-
inﬂammatory state of an acute MI may inﬂuence the
effect of the cardioprotective strategy. Finding an
animal model to reproduce these effects is a daunting
task.
The clinical setting which most closely resembles the
most frequently used animal model of MI is the IHD
patient presenting acutely with a complete thrombotic
coronary artery occlusion (a ST-elevation myocardial
infarction, STEMI) undergoing myocardial reperfu-
sion using PCI. Whether this animal MI model should
be used to investigate novel cardioprotective strate-
gies destined for use in different clinical settings such
as cardiac arrest, cardiac transplantation, PCI or
CABG surgery may be questioned. However, other
more appropriate animal models are available to
simulate the myocardial injury sustained in these
clinical settings (see Table 1).
2. Duration of ischemia The index ischemic time used in
animal MI models is usually ﬁxed having been
selected to create a moderate to large infarct when
expressed as the area at risk (AAR), but still allowing
for protection to occur [42]. Furthermore, due to the
ﬁxed ischemic time the variation of the extent of MI is
relatively small making any demonstration of cardio-
protection easier. In contrast, MI patients present with
widely varying ischemic times at the hospital (in the
range of 1–12 h) and display huge variability in MI
size even allowing for the same ischemic time because
of the large number of confounding factors which can
inﬂuence infarct size. Therefore, the demonstration of
any kind of cardioprotection is complicated, requiring
quite often subgroup analyses of patient data, thereby
increasing the sample size.
Table 1 Matching the animal IRI model for investigating the novel cardioprotective strategy to the clinical setting in which it is intended for use
Clinical setting Animal IRI model Example animal
studies
STEMI patient undergoing PCI
(regional acute myocardial ischemia and reperfusion)
Animal model of MI
(regional acute myocardial ischemia and reperfusion)
Mice, rats,
rabbits, dogs
and pigs [56]
Stable IHD patient undergoing CABG surgery (global myocardial
ischemia and reperfusion with cardioplegia, coronary
microembolization and manual handling)
Use of cardio-pulmonary bypass for circulatory support
(global myocardial ischemia and
reperfusion ± cardioplegia)
Dogs, pigs and
sheep [30, 31]
Cardiac arrest patient in which circulation has been restored
(global myocardial ischemia and reperfusion)
Animal model of cardiac arrest and reperfusion
(global myocardial ischemia and reperfusion)
Rats [59] and
pigs [40]
Cardiac transplant patient (global myocardial ischemia and
reperfusion with cardioplegia)
Heterotopic heart transplantation with global
myocardial ischemia and reperfusion ± cardioplegia
Pigs [34]
Patient undergoing PCI (limited myocardial ischemic injury and
coronary microembolization)
Coronary microembolization Pigs [52]
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1233. Duration of reperfusion The reperfusion time used in
animal MI models is usually ﬁxed and ranges from 0.5
to 3 h depending on the particular model used. In rat
and rabbit in vivo models the ultimate MI size by
tetrazolium staining has been reported to be estab-
lished after 3 h of reperfusion [67]. However, studies
suggest that MI size in the canine heart continues to
increase even after 6 h of reperfusion [68], although
this issue is controversial [16]. For MI patients, the
duration of reperfusion obviously depends on the time
when one measures MI size. Therefore, the acute
infarct-limiting effects of a novel cardioprotective
strategy should be assessed when infarct size is fully
developed but before remodelling occurs.
4. Endpoint of cardioprotection In most animal experi-
ments, the reduction of MI size is taken as the endpoint
of cardioprotection. MI size depends on the area at risk
and on residual blood ﬂow, and therefore MI size as a
fraction of area at risk is the more robust endpoint of
protection.TherelationofMIsizeasafractionofAARto
residual blood ﬂow is probably the best endpoint of
cardioprotectioninanimalexperiments[53].Recoveryof
contractile function is not only a function of MI size, but
alsoofstunningandthereforelesssuitedasanendpointof
protection.Ofnote,inclinicalstudiesMIsizeisestimated
from biomarkers and imaging and considered only a
surrogate for clinical outcome.
It is clear from the previously published preclinical lit-
erature that an abundance of novel cardioprotective strat-
egies have been discovered. However, the investigation of
a particular novel cardioprotective strategy using a sys-
tematic, step-wise, collaborative approach has been lack-
ing. Therefore, the formation of a collaborative network of
research laboratories to test a single novel cardioprotective
strategy in a range of animal MI models may be required to
determine whether consistent cardioprotection is observed
across species and laboratories. This would have the
potential advantage of increasing the probability of a suc-
cessful translation into the clinical setting, or alternatively,
discouraging the initiation of a clinical trial that is destined
to be unsuccessful. In 2002, this approach was used to
investigate the cardioprotective effect of an adenosine A1
agonist. In this study, a multicentre randomised controlled
double-blind experimental animal study was performed in
three different laboratories [4].
Clinical settings of IRI
The pathophysiology of IRI obviously varies with the
clinical setting. The purest example of classical IRI is the
IHD patient presenting acutely with a complete thrombotic
coronary artery occlusion (a STEMI) who undergoes PCI
reperfusion therapy. Although IRI may contribute to the
myocardial injury sustained in a number of other clinical
settings such as CABG surgery, cardiac arrest and trans-
plantation, other factors such as manual handling of the
heart and coronary embolization [23] may come into play.
They need to be taken into consideration when analysing
the results. It should be noted, however, that the problem of
distal embolization may also occur with PCI and the con-
tribution of IRI per se to this form of injury is probably
minor. Clearly, the appropriate animal IRI model should be
selected to test the novel cardioprotective strategy to match
the intended clinical setting in which it is to be applied to
(see Table 1).
Designing clinical cardioprotective studies of STEMI
patients undergoing PCI
The patient
1. Site of the infarct A recent analysis has suggested that
only 25% of all STEMI patients will have infarcts
large enough to realize beneﬁt from any adjunctive
therapy applied at the time of PCI [38]. Thus, the PCI
patients who are most likely to beneﬁt immediately
from a cardioprotective strategy in the short term are
those patients in whom the therapy is applied as an
adjunct to reperfusion therapy and in those which have
the larger areas at risk. In general these are patients
who present with proximal LAD coronary artery ter-
ritory infarcts. In contrast, patients presenting with the
smaller areas at risk, such as those in the right coronary
artery (RCA) and circumﬂex (Cx) coronary artery
territories do not appear to accrue as much beneﬁt
from cardioprotective reperfusion therapy [8, 43].
Selecting patients with the smaller infarcts may
therefore actually dilute any positive effect elicited by
the novel cardioprotective strategy. As such, clinical
studies should focus on selecting patients presenting
with a proximal LAD infarct only [42]. The disad-
vantage of this approach is that it may impact nega-
tively on recruitment rates as this population only
makes up 30% of all presenting STEMI patients. It is
therefore clear that the AAR should be measured when
assessing any novel cardioprotective strategy in the
clinical setting.
2. TIMI ﬂow prior to PCI For cardioprotective strategies
applied at the time of PCI, it is essential that the
intervention is administered prior to myocardial
reperfusion. Therefore, patients in which the infarct-
related coronary artery has spontaneously recanalized
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already undergone myocardial reperfusion and are
unlikely to beneﬁt from the novel cardioprotective
strategy and should be excluded. However, this may
not be so straightforward, given that some patients can
have intermittent reperfusion prior to the catheter
laboratory, but have TIMI 0/1 ﬂow prior to PCI.
Recent studies suggest that the patients most likely to
beneﬁt from a novel cardioprotective strategy applied
at the time of PCI are those presenting with TIMI 0/1
ﬂow in the culprit coronary artery [8].
3. Coronary collaterals The presence of coronary collat-
eralisation to the area at risk will reduce MI size in
STEMI patients undergoing PCI, thereby confounding
any potential beneﬁcial effect with the novel cardio-
protective strategy. Patients with visible coronary
collaterals (Rentrop grade C 1) [46] on coronary
angiography should be excluded from the study.
Therefore, it is essential to ensure that the image
acquisitions taken during coronary angiography are
long enough to visualise coronary collaterals.
4. Duration of chest pain It has been established that
STEMI patients accrue mortality beneﬁt from myo-
cardial reperfusion strategies such as thrombolysis and
PCI providing they present within 12 h of the onset of
chest pain [17]. Therefore, cardioprotection studies
have tended to focus on those patients presenting
within 12 h of chest pain onset. The relationship
between the extent of lethal myocardial reperfusion
injury and the duration of index ischemia has not been
fully elucidated. Whether patients with short ischemic
times (\3 h chest pain to PCI time) or patients with
prolonged ischemic times (6–12 h chest pain to PCI
time) accrue more beneﬁt from an adjunctive reperfu-
sion treatment strategy is unclear. Indeed whether
patients who present more than 12 h following the
onset of chest pain, beneﬁt from adjunctive therapy to
PCI is unknown.
5. Measurement of the area at risk The assessment of the
efﬁcacy of a novel cardioprotective strategy in PCI
patients requires the measurement of both the MI size
and the area at risk (AAR). This allows a comparison
between STEMI patients with different AAR. Histor-
ically, the AAR has been measured in clinical studies
using coronary angiography jeopardy scores but the
traditional gold-standard technique has been to use
nuclear myocardial scanning [8]. The AAR is delin-
eated as the areas of absent radioisotope tracer on a
nuclear myocardial scan performed within 6 h of the
injection. Quantiﬁcation of the AAR by nuclear
myocardial scanning can take into account coronary
collateralisation because the radioisotope is able to
distribute through the collaterals and reduce the AAR,
and hence myocardial salvage can be determined
correctly even in the presence of coronary collaterals.
However, this technique is time-consuming, impracti-
cal when offered on a 24-h daily basis, lacks resolution
and involves signiﬁcant radiation to the patient.
An alternative approach to measure the AAR is to assess
the hypokinetic segments of the left ventricle using ven-
ticulography at the time of PCI [57, 60], although this
technique may overestimate the AAR by including areas of
myocardial stunning. Cardiac MRI (CMR) may be a
promising imaging technique for measuring the AAR.
Animal studies have reported that enhanced signal intensity
on retrospective T2-weighted CMR from increased myo-
cardial oedema [10] correlates with the AAR in reperfused
myocardial infarcts [1, 27]. Preliminary clinical studies
suggest that the enhanced T2 signal intensity on CMR
scans performed in the ﬁrst week following PCI correlates
with the AAR as measured by the BARI coronary angi-
ography jeopardy score [65] and nuclear myocardial scans
[11]. In addition, myocardial salvage as measured by CMR
has been linked to clinical outcomes in PCI-treated STEMI
patients [14]. The concern with CMR is whether the novel
cardioprotective strategy itself may inﬂuence the extent of
myocardial oedema by reducing it, thereby resulting in an
underestimate of the AAR. In this case, CMR may be
ineffective as a technique for measuring AAR post PCI.
Whichever technique is used to measure the AAR it is
essential to use the AAR as a co-variate for analysing MI
size reduction, given that patients presenting with the lar-
ger areas at risk are those most likely to beneﬁt from the
novel cardioprotective strategy.
The intervention
1. Timing of the cardioprotective strategy The timing of
the cardioprotective strategy is critical in the design of
clinical studies. The refusal to take heed of preclinical
data has been the root cause for some major failures in
the clinical ﬁeld of cardioprotection. Some strategies
like sodium–hydrogen exchange inhibitors or thera-
peutic cooling target myocardial ischemia, while other
strategies such as ischemic and pharmacologic post-
conditioning and remote ischemic conditioning target
myocardial reperfusion injury. A cardioprotective
strategy which targets myocardial ischemia may still
be effective if administered soon after ischemia has
started. Such an intervention could be applied by the
paramedics in the ambulance, particularly where long
transit times to the PCI centre are anticipated and
should be encouraged [8]. The ambulance is also the
ideal setting for remote ischemic conditioning but
often the transit time is too short to complete the
Basic Res Cardiol (2010) 105:677–686 681
123treatment protocol [8]. Whatever the case, it is essen-
tial that any cardioprotective strategy be applied prior
to the opening of the infarct-related coronary artery,
given the crucial events which occur in the ﬁrst few
minutes of myocardial reperfusion [production of
oxidative stress, calcium overload and mitochondrial
permeability transition pore (mPTP) opening] [42, 66].
Clearly, it is imperative that the application of the
novel cardioprotective strategy does not in any way
delay the onset of myocardial reperfusion.
2. Delivery of cardioprotective strategy A number of
pharmacologic postconditioning agents have been
identiﬁed (e.g. cyclosporine-A). Any such drug should
be capable of being administered as a single intrave-
nous or intracoronary bolus so that therapeutic levels
will be achieved in a matter of minutes.
Clinical cardioprotective studies of patients undergoing
CABG surgery
The patient
Despite excellent cardioprotection using cold blood cardi-
oplegia, signiﬁcant peri-operative myocardial injury still
occurs in patients undergoing CABG surgery ± valve
surgery. The cause of this myocardial injury is multi-fac-
torial being attributed to global ischemia–reperfusion
injury, coronary embolization and prolonged aortic cross-
clamp time. The extent of peri-operative myocardial injury
can be assessed by measuring serum cardiac enzymes such
as CK-MB, troponin-T and troponin-I, the elevation of
which has been associated with worse clinical outcomes
post-surgery [9, 13, 29]. Surgeons are therefore continually
seeking ways to minimise IRI, particularly as more high-
risk patients are being operated upon and it is becoming
increasingly clear that even mild to moderate elevations in
CK-MB and troponin are associated with increased inter-
mediate and long-term mortality.
Similar to the setting of a STEMI in which patients with
a larger MI are most likely to beneﬁt from a cardiopro-
tective intervention, the same may apply to patients
undergoing CABG surgery. Therefore, the patients most
likely to beneﬁt from a cardioprotective strategy during
CABG surgery are those who are most at risk of sustaining
signiﬁcant peri-operative myocardial injury. This group
includes patients undergoing 3-vessel CABG surgery with
or without valve surgery, redo CABG surgery patients,
patients with signiﬁcant LVH or LV systolic dysfunction,
patients with an additive Euroscore of C6 and diabetic
patients. We believe that it is this group of higher-risk
patients who should be selected for studies of novel
cardioprotective strategies as they are more likely to
experience a greater degree of myocardial IRI from the
prolonged cross-clamp and cardio-pulmonary bypass times.
The intervention
A variety of cardioprotective strategies have been tried in
the CABG surgery setting in the past. Although the
majority of these were unsuccessful, one of the most
potentially promising treatment strategies was cariporide,
but unfortunately it had off-target cerebral side effects [37].
In the setting of CABG surgery, the novel cardioprotective
strategy can be applied either prior to myocardial ischemia
(cross-clamping of the aorta), during myocardial ischemia
in the cardioplegia solution or at the time of myocardial
reperfusion (unclamping the aorta). As noted previously,
the preclinical testing of the novel cardioprotective strategy
in an animal IRI model which closely resembles the CABG
setting should have been previously utilised to verify efﬁ-
cacy (see Table 1).
Which novel cardioprotective strategy should be
pursued in the clinical setting?
There are a number of novel cardioprotective strategies
which have shown promise in initial proof-of-concept
clinicalstudies.Thequestioniswhichoftheseshouldbetaken
forward into phase 2/3 clinical studies. Following discussion
in the Workshop, it was agreed that the two most promising
novel cardioprotective strategies were remote ischemic con-
ditioning (RIC) and cyclosporine-A (CsA).
For RIC, in which cycles of brief ischemia and reper-
fusion applied to the upper or lower limb protect the
myocardium from lethal IRI, there exist extensive pre-
clinical data in a range of animal models including in vivo
murine, rat, rabbit and porcine models of MI (reviewed
in [20, 56]). RIC is a non-invasive virtually cost-free
cardioprotective strategy which has been shown to be
effective when applied both prior to or during the index
myocardial ischemia [47] as well as at the onset of
myocardial reperfusion [2], lending itself to the clinical
settings of CABG surgery [18], planned PCI [25], and
STEMI patients receiving PCI [8], settings in which initial
proof-of-concept studies have already been successfully
performed.
CsA has the advantage of targeting an end-effector of
IRI, as opposed to the ever-expanding list of cardiopro-
tective agents which tend to target G-protein coupled
receptors and intracellular kinases and other mediators,
which may be down-regulated or ineffective in the pres-
ence of co-morbidities. Because the main site of action of
CsA is probably the mPTP, a purported mitochondrial
channel which mediates cardiomyocyte death at the onset
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support of its role as a cardioprotective agent have been as
an adjunct to myocardial reperfusion [19, 22]. Similarly,
there exist extensive preclinical data in a range of animal
models including in vitro and in vivo models of MI, as well
as in a rabbit model of post-cardiac arrest [12]. However,
the in vivo porcine MI model has produced mixed results
with CsA for an unclear reason [28, 35, 54]. CsA has also
been demonstrated to be effective in human atrial tissue
models of simulated IRI [49]. Again, a preliminary proof-
of-concept clinical study has demonstrated that a single
intravenous bolus of CsA given prior to PCI can limit MI
size in STEMI patients [43].
Other potentially novel cardioprotective strategies for
which there exist both preclinical data and initial proof-of-
concept clinical studies are glucagon-like peptide 1 [41],
PKC-d inhibition [3], atrial natriuretic peptide [32], and
ischemic postconditioning [60].
Clearly, for all these novel cardioprotective strategies
preclinical studies are required to determine whether car-
dioprotection is maintained in the presence of certain
confounding factors such as age, sex, diabetes, the meta-
bolic syndrome, hyperlipidemia, hypertension and so forth.
In this regard, a recent preclinical study suggests that CsA-
mediated cardioprotection at the time of myocardial
reperfusion was ineffective in Zucker obese rats [26]. This
intriguing ﬁnding requires conﬁrmation and the mechanism
underlying this observation needs further investigation.
In summary, for both CsA and RIC large multi-centred
randomised controlled clinical trials are required to conﬁrm
their cardioprotective beneﬁt in the clinical setting and
investigate whether these interventions impact on clinical
outcomes for patient beneﬁt.
Summary
In order to overcome the obstacles to translation of novel
cardioprotective strategies discovered in laboratories into
the clinical setting for patient beneﬁt, a set of recommen-
dations may facilitate this process. These are outlined
below and include preclinical cardioprotection studies and
clinical cardioprotection studies in PCI patients. Clearly,
similar recommendations may be introduced for other
clinical settings of IRI such as CABG surgery, sudden
cardiac arrest, cardiac transplantation, as more evidence
becomes available from ongoing studies.
Recommendations for investigating novel
cardioprotective strategies in preclinical studies
1. In vitro models A novel cardioprotective strategy
should be ﬁrst investigated using established small
animal (murine, rat, rabbit) in vitro models of IRI,
including human myocardial tissue models of simu-
lated IRI [51, 64]. The actual animal IRI model used
should closely resemble the clinical setting in which it
intended to test the novel cardioprotective strategy (see
Table 1).
2. In vivo models The novel cardioprotective strategy
should then be examined ﬁrst in small (murine, rat,
rabbit) and then in large animal (pig, dog, primate) in
vivo studies of IRI. Again, the actual animal IRI model
used should closely resemble the clinical setting in
which it is intended to test the novel cardioprotective
strategy (see Table 1). For animal MI models, reper-
fusion must be of sufﬁcient duration such that MI size
has fully developed; on the other hand, infarct size
must be determined before remodelling occurs.
3. Confounders Ideally, the cardioprotective strategy
should be demonstrated to still be effective in the
presence of one or more confounders and/or medical
therapies.
Recommendations for investigating novel
cardioprotective strategies in PCI studies
1. Proximal LAD infarcts STEMI patients presenting
with a proximal LAD coronary artery infarct are pre-
ferred as these patients are those most likely to beneﬁt
from the novel cardioprotective strategy.
2. TIMI 0 or 1 prior to PCI Only STEMI patients
presenting with TIMI 0/1 coronary ﬂow on coronary
angiography prior to PCI should be included in studies
investigating novel cardioprotective strategies.
3. No collaterals on coronary angiography Only STEMI
patients with no visible coronary collaterals on coro-
nary angiography should be included in studies
investigating novel cardioprotective strategies. The
exception to this is if the AAR is being measured using
nuclear myocardial scanning which takes into account
coronary collateralisation.
4. Chest pain \12 h Only STEMI patients presenting
within 12 h of the onset of chest pain should be
included in studies investigating novel cardioprotec-
tive strategies.
5. Cardioprotective strategy applied prior to reperfusion
The intervention must be applied prior to the opening
of the culprit coronary artery.
6. Measurement of the area at risk When assessing the
efﬁcacy of a novel cardioprotective strategy it is
imperative to measure the area at risk.
7. Assessment of the cardioprotective strategy In proof-
of-concept clinical studies it may be sufﬁcient to
measure serum cardiac enzymes (CK-MB and
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123troponin-T or I). However, more robust surrogate
clinical endpoints include LV ejection fraction (mea-
sured by echocardiography, myocardial nuclear scan-
ning or cardiac MRI) and MI size (measured by
myocardial nuclear scanning or cardiac MRI). Ulti-
mately, clinical outcome measures such as cardiovas-
cular mortality and hospitalization for heart failure
must be determined.
Recommendations for investigating novel
cardioprotective strategies in CABG studies
1. Patient selection The investigation of a novel cardio-
protective strategy should focus on those patients more
likely to sustain signiﬁcant peri-operative myocardial
injury during surgery. These include patients with left
ventricular hypertrophy (LVH) or impaired left ven-
tricular (LV) systolic function and patients undergoing
3-vessel CABG ± valve surgery or redo CABG sur-
gery and diabetic patients.
2. Anaesthetic choice The investigation of the novel
cardioprotective strategy should not inﬂuence the
choice of anaesthetic regimen, even if it comprises
inhaled anaesthetic agents such as isoﬂurane, which
have been reported in both preclinical and clinical
studies to confer cardioprotection during CABG sur-
gery [58]. It is important that any novel cardioprotec-
tive strategy is shown to be effective in the presence of
routine medical therapy.
3. Assessment of the cardioprotective strategy In proof-
of-concept clinical studies, peri-operative release of
cardiac enzymes such as CK-MB, troponin-T or I can
be used to assess the efﬁcacy of the novel cardiopro-
tective strategy [18, 61]. Other clinical endpoints
include: inotrope score, length of ITU and hospital
stay, LV ejection fraction, acute kidney injury, cogni-
tive function, cardiovascular mortality, and hospital-
ization for heart failure.
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